Other
Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression
Justine E Marum, Leanne Purins, David T Yeung, Wendy Tara Parker, David J Price, Paul PS Wang, Doris Stangl, Jasmina Geogievski, Bradley Chereda, Andreas Schreiber, Simon J Tuke, Timothy P Hughes, Susan Branford
BLOOD | AMER SOC HEMATOLOGY | Published : 2015
Abstract
Abstract Background: Scoring systems at CML diagnosis, such as Sokal risk, provide important response prediction for imatinib (IM) treated patients (pts). Specific treatment policies have been suggested for high risk pts to optimize otherwise inferior outcomes. However, responses among pts with high risk are heterogeneous and new biomarkers are required to facilitate rational selection of optimal therapy. Biological factors, such as germline genetic variation, may play a role in therapy response dynamics. We aimed to identify predictive biomarkers of response to IM at CML diagnosis to aid selection of front line therapy for optimal treatment outcomes. ..
View full abstract